Selenium Supplementation and Prostate Health in a New Zealand Cohort

There is variable reporting on the benefits of a 200 μg/d selenium supplementation towards reducing prostate cancer impacts. The current analysis is to understand whether stratified groups receive supplementation benefits on prostate health. 572 men were supplemented with 200 µg/d selenium as selinized yeast for six months, and 481 completed the protocol. Selenium and prostate-specific antigen (PSA) levels were measured in serum at pre- and post-supplementation. Changes in selenium and PSA levels subsequent to supplementation were assessed with and without demographic, lifestyle, genetic and dietary stratifications. The post-supplementation selenium ( = 0.002) and the gain in selenium ( < 0.0001) by supplementation were significantly dependent on the baseline selenium level. Overall, there was no significant correlation between changes in PSA and changes in selenium levels by supplementation. However, stratified analyses showed a significant inverse correlation between changes in PSA and changes in selenium in men below the median age ( = 0.048), never-smokers ( = 0.031), men carrying the GPX1 rs1050450 T allele (CT, = 0.022 and TT, = 0.011), dietary intakes above the recommended daily intake (RDI) for zinc ( < 0.05), and below the RDI for vitamin B12 ( < 0.001). The current analysis shows the influence of life factors on prostate health benefits of supplemental selenium.